Inactive Instrument

News Annexin Pharmaceuticals AB (publ) Nasdaq Stockholm

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioStock: Annexin's phase II study fully recruited with positive signals	Apr. 30	AQ
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	Apr. 30	CI
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	Apr. 25	AQ
Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	Apr. 25	CI
BioStock: Annexin towards completion of phase II study and share issue	Apr. 18	AQ
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 12	CI
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	Mar. 28	AQ
BioStock: Strong start for Annexin in 2024	Feb. 14	AQ
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Update on Annexin´s RVO study confirms promising signals of effect	Feb. 08	AQ
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	Feb. 08	CI
Annexin presents at Redeye’s Fight Cancer event on January 24	Jan. 18	AQ
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	Dec. 18	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	Nov. 30	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	Nov. 28	AQ
First patients treated with higher dose without adverse events in Annexin's RVO study	Nov. 23	AQ
Annexin granted additional patent protection in the US	Nov. 14	AQ
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	Nov. 14	CI
First patient treated in the second dose group in Annexin's RVO study	23-10-25	PR
First patient treated in the second dose group in Annexin's RVO study	23-10-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Annexin Pharmaceuticals AB (publ) Nasdaq Stockholm

Equities

Summary

Filters